View ValuationHumedix 향후 성장Future 기준 점검 1/6Humedix (는) 각각 연간 19.1% 및 8.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.6% 로 예상됩니다.핵심 정보19.1%이익 성장률19.00%EPS 성장률Pharmaceuticals 이익 성장20.4%매출 성장률8.9%향후 자기자본이익률17.55%애널리스트 커버리지Low마지막 업데이트24 Apr 2026최근 향후 성장 업데이트Major Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.모든 업데이트 보기Recent updatesUpcoming Dividend • May 19Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 26 May 2026. Payment date: 15 June 2026. Trailing yield: 2.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.9%).New Risk • Apr 23New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Mar 26Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 02 April 2026. Payment date: 22 April 2026. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).공시 • Mar 17Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaMajor Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.Upcoming Dividend • Nov 17Upcoming dividend of ₩570 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 11 December 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.8%).New Risk • Sep 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Aug 16Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 20 August 2025. Payment date: 05 September 2025. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Upcoming Dividend • Jun 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 22 August 2025. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.0%).Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.New Risk • May 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.공시 • May 08Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 5,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with SAMSUNG SECURITIES Co., Ltd. The purpose of the program is to improve shareholder value. The program will expire on November 7, 2025. As of May 6, 2025, the company had 885,401 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.New Risk • Apr 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Mar 21Upcoming dividend of ₩330 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 April 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).공시 • Mar 13Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea공시 • May 25Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on November 26, 2024. As of May 23, 2024, the company had 810,507 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.Upcoming Dividend • Mar 22Upcoming dividend of ₩275 per shareEligible shareholders must have bought the stock before 29 March 2024. Payment date: 19 April 2024. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).공시 • Sep 28Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 27, 2023. As of March 15, 2022, the company had 680,117 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.공시 • Jun 24An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion.An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion on June 22, 2022. The transaction is resolved by the board of Humedix and expected to complete on June 30, 2022.Buying Opportunity • Mar 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.Buying Opportunity • Feb 14Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩38,700, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.Reported Earnings • May 12First quarter 2021 earnings released: EPS ₩330 (vs ₩99.00 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩28.4b (up 48% from 1Q 2020). Net income: ₩3.11b (up 215% from 1Q 2020). Profit margin: 11% (up from 5.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩38,850, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩35,750, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 4.6% over the past three years.공시 • Apr 07Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investorsOn April 6, 2021, Humedix Co., Ltd. (KOSDAQ:A200670) closed the transaction.Reported Earnings • Mar 14Full year 2020 earnings released: EPS ₩1,587 (vs ₩1,094 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩98.5b (up 25% from FY 2019). Net income: ₩15.1b (up 45% from FY 2019). Profit margin: 15% (up from 13% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.분석 기사 • Mar 09Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Feb 20New 90-day high: ₩26,050The company is up 5.0% from its price of ₩24,800 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩26,050, the stock is trading at a trailing P/E ratio of 21.9x, up from the previous P/E ratio of 18.4x. This compares to an average P/E of 28x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 31%.분석 기사 • Feb 16Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Most readers would already be aware that Humedix's (KOSDAQ:200670) stock increased significantly by 11% over the past...분석 기사 • Jan 28Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?Today we'll take a closer look at Humedix Co., Ltd. ( KOSDAQ:200670 ) from a dividend investor's perspective. Owning a...Is New 90 Day High Low • Jan 18New 90-day low: ₩21,250The company is down 12% from its price of ₩24,050 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.분석 기사 • Jan 11Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...분석 기사 • Dec 22What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...Upcoming Dividend • Dec 22Upcoming Dividend of ₩400 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.1% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.6%).분석 기사 • Dec 01Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Oct 23New 90-day low: ₩23,500The company is down 17% from its price of ₩28,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: ₩24,050The company is down 6.0% from its price of ₩25,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.이익 및 매출 성장 예측KOSDAQ:A200670 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2027199,20042,000N/A59,000112/31/2026189,40040,100N/A50,300112/31/2025171,50051,75020,00049,800112/31/2024168,40036,90037,76753,300212/31/2023154,00029,30032,00034,000112/31/2021110,9929,0654,44119,185N/A9/30/2021115,57215,04014,22526,946N/A6/30/2021111,60015,98817,40128,724N/A3/31/2021107,72417,20410,43624,961N/A12/31/202098,48115,0846,07023,762N/A9/30/202085,72111,348-3,19914,176N/A6/30/202084,84410,717-1,45014,820N/A3/31/202080,9689,0232,61112,695N/A12/31/201978,61910,4204,46913,810N/A9/30/201973,5019,6734,69919,280N/A6/30/201968,8599,888-1,52918,138N/A3/31/201967,3519,5567,98126,417N/A12/31/201864,8329,2087,03423,803N/A9/30/201862,0179,1856,17117,454N/A6/30/201858,6709,6105,98414,378N/A3/31/201856,40111,719-5,59211,764N/A12/31/201754,72711,940-10,7328,765N/A9/30/201754,39111,385-20,9443,183N/A6/30/201751,75310,332-17,2858,250N/A3/31/201749,0519,449-17,9391,896N/A12/31/201647,13410,275-14,7897,609N/A12/31/201542,13311,62387111,706N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A200670 의 연간 예상 수익 증가율(19.1%)이 saving rate(3.1%)보다 높습니다.수익 vs 시장: A200670 의 연간 수익(19.1%)이 KR 시장(29.3%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: A200670 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: A200670 의 수익(연간 8.9%)이 KR 시장(연간 16.5%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: A200670 의 수익(연간 8.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A200670의 자본 수익률은 3년 후 17.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 15:12종가2026/05/22 00:00수익2021/12/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Humedix Co., Ltd.는 9명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kevin JinDaiwa Securities Co. Ltd.null nullDBS Bank LtdSang-Hun LeeiM Securities6명의 분석가 더 보기
Major Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.
Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.
Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.
Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.
Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.
Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.
Upcoming Dividend • May 19Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 26 May 2026. Payment date: 15 June 2026. Trailing yield: 2.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.9%).
New Risk • Apr 23New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Mar 26Upcoming dividend of ₩200 per shareEligible shareholders must have bought the stock before 02 April 2026. Payment date: 22 April 2026. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).
공시 • Mar 17Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
Major Estimate Revision • Feb 21Consensus EPS estimates increase by 16%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week.
Price Target Changed • Dec 03Price target increased by 13% to ₩61,000Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year.
Upcoming Dividend • Nov 17Upcoming dividend of ₩570 per shareEligible shareholders must have bought the stock before 24 November 2025. Payment date: 11 December 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.8%).
New Risk • Sep 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Aug 16Upcoming dividend of ₩150 per shareEligible shareholders must have bought the stock before 20 August 2025. Payment date: 05 September 2025. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Upcoming Dividend • Jun 20Upcoming dividend of ₩300 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 22 August 2025. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.0%).
Major Estimate Revision • May 21Consensus EPS estimates increase by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week.
New Risk • May 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
공시 • May 08Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 5,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with SAMSUNG SECURITIES Co., Ltd. The purpose of the program is to improve shareholder value. The program will expire on November 7, 2025. As of May 6, 2025, the company had 885,401 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.
New Risk • Apr 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Mar 21Upcoming dividend of ₩330 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 April 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
공시 • Mar 13Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
공시 • May 25Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on November 26, 2024. As of May 23, 2024, the company had 810,507 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.
Price Target Changed • Apr 14Price target increased by 17% to ₩56,000Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year.
Upcoming Dividend • Mar 22Upcoming dividend of ₩275 per shareEligible shareholders must have bought the stock before 29 March 2024. Payment date: 19 April 2024. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Price Target Changed • Jan 19Price target decreased by 15% to ₩56,000Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year.
Major Estimate Revision • Nov 15Consensus EPS estimates fall by 11%, revenue upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
공시 • Sep 28Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares.Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 27, 2023. As of March 15, 2022, the company had 680,117 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase.
공시 • Jun 24An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion.An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion on June 22, 2022. The transaction is resolved by the board of Humedix and expected to complete on June 30, 2022.
Buying Opportunity • Mar 11Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.
Buying Opportunity • Feb 14Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years.
Upcoming Dividend • Dec 22Upcoming dividend of ₩400 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩38,700, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years.
Reported Earnings • May 12First quarter 2021 earnings released: EPS ₩330 (vs ₩99.00 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩28.4b (up 48% from 1Q 2020). Net income: ₩3.11b (up 215% from 1Q 2020). Profit margin: 11% (up from 5.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩38,850, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improved over the past weekAfter last week's 40% share price gain to ₩35,750, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 4.6% over the past three years.
공시 • Apr 07Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investorsOn April 6, 2021, Humedix Co., Ltd. (KOSDAQ:A200670) closed the transaction.
Reported Earnings • Mar 14Full year 2020 earnings released: EPS ₩1,587 (vs ₩1,094 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩98.5b (up 25% from FY 2019). Net income: ₩15.1b (up 45% from FY 2019). Profit margin: 15% (up from 13% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 09Humedix (KOSDAQ:200670) Has A Pretty Healthy Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Feb 20New 90-day high: ₩26,050The company is up 5.0% from its price of ₩24,800 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩26,050, the stock is trading at a trailing P/E ratio of 21.9x, up from the previous P/E ratio of 18.4x. This compares to an average P/E of 28x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 31%.
분석 기사 • Feb 16Humedix Co., Ltd.'s (KOSDAQ:200670) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Most readers would already be aware that Humedix's (KOSDAQ:200670) stock increased significantly by 11% over the past...
분석 기사 • Jan 28Should You Buy Humedix Co., Ltd. (KOSDAQ:200670) For Its Dividend?Today we'll take a closer look at Humedix Co., Ltd. ( KOSDAQ:200670 ) from a dividend investor's perspective. Owning a...
Is New 90 Day High Low • Jan 18New 90-day low: ₩21,250The company is down 12% from its price of ₩24,050 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.
분석 기사 • Jan 11Are Humedix's (KOSDAQ:200670) Statutory Earnings A Good Reflection Of Its Earnings Potential?As a general rule, we think profitable companies are less risky than companies that lose money. That said, the current...
분석 기사 • Dec 22What Type Of Returns Would Humedix's(KOSDAQ:200670) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩400 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.1% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.6%).
분석 기사 • Dec 01Here's Why Humedix (KOSDAQ:200670) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Oct 23New 90-day low: ₩23,500The company is down 17% from its price of ₩28,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: ₩24,050The company is down 6.0% from its price of ₩25,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.